From professional translators, enterprises, web pages and freely available translation repositories.
not estimable
ma jistax jiġi stmat
Last Update: 2012-04-10
Usage Frequency: 2
Quality:
ne = not estimable
me = mhux stmat
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
ci, confidence interval; ne, not estimable.
ci, intervall tal-kunfidenza; ne, mhux estimabbli.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
ne = not estimable. a the median is based on kaplan-meier estimate.
ne = ma jistax jiġi stmat. a il-medjan hu bbażat fuq stima ta’ kaplan-meier.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
13.8, not estimable) in the panitumumab arm and not estimable in the non-panitumumab arm.
13. 8, ma jistax jiġi stmat) fil- grupp b’ panitumumab u ma setax jiġi stmat fil- grupp mhux b’ panitumumab.
Last Update: 2012-04-10
Usage Frequency: 2
Quality:
the median duration of response was not estimable (four patients experienced disease progressions following an objective response).
it-tul medjan sa rispons ma setgħax jiġi stmat (erba’ pazjenti kellhom progressjoni tal-marda wara rispons oġġettiv).
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
the median duration of response by irc was not reached (95% ci, 4.6 months to not estimable).
it-tul medjan tar-rispons minn irc ma ntlaħaqx (ci ta’ 95%, 4.6 xhur sa ma jistax jiġi stmat).
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
alp = alkaline phosphatase; ci = confidence interval; ne = not estimable; psa = prostate-specific antigen;
alp = alkaline phosphatase; ci = intervall ta’ kunfidenza; ne = ma jistax jiġi stmat; psa = antiġen speċifiku għall-prostata;
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
drop outs due to reasons other than treatment failure were censored at the time of dropping out. a hr of adalimumab vs placebo from proportional hazards regression with treatment as factor. b 2-sided p value from log rank test. c ne = not estimable.
dawk li waqfu minħabba raġunijiet oħra għajr il- falliment tat-trattament kienu ċensurati fi żmien li waqfu. a hr ta’ adalimumab vs plaċebo minn rigressjoni ta’ perikli li huma proporzjonali mat-trattament bħala fattur. b 2-naħat valur p minn test log rank. c ne = mhux stmat.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
note: ci=confidence interval; irac=independent review adjudication committee; ne = not estimable. a the median is based on kaplan-meier estimate.
nota: ci=intervall tal-kunfidenza; irac=kumitat indipendenti ta’ evalwazzjoni; ne = ma jistax jiġi stmat. a il-medjan hu bbażat fuq stima ta’ kaplan-meier.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
the nnt for the total paediatric population was 9 (95 % ci 7 – 24) and 8 (95 % ci 6, upper limit not estimable) in the whole population (itt) and in paediatric contacts of infected index cases (ittii), respectively.
l-nnt għall-popolazzjoni pedjatrika totali kien ta’ 9 (95 % ci 7 - 24) u 8 (95 % ci 6, limitu ta’ fuq mhux stmat) fil-popolazzjoni kollha (itt) u f’kuntatti pedjatriċi ta’ każijiet indiċi infettati (ittii), rispettivament.
Last Update: 2017-04-26
Usage Frequency: 3
Quality: